参一胶囊在晚期非小细胞肺癌维持治疗中的疗效观察  

Effectiveness and safety of single-agent ginsenoside Rg3 maintenance therapy after response to first-line chemotherapy in patients with advanced non-small cell lung cancer

作　　者：曾冬香[1] 毕延智[1] 盛桂凤[1] 董益忠[1] 宋红蕾[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,常州213001

出　　处：《癌症进展》2013年第6期554-557,561,共5页Oncology Progress

摘　　要：目的观察晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)一线化疗获益的患者后续参一胶囊维持治疗的疗效与不良反应。方法初治、晚期NSCLC患者一线化疗最多6个周期后疗效评价无疾病进展的患者随机分组,35例进入观察组,仅接受定期随访观察,34例进入治疗组,接受参一胶囊维持治疗,维持治疗持续到疾病进展或出现患者不能耐受为止。结果随访过程中治疗组有2例患者退出或失访,治疗组与观察组的疾病进展率分别为53.1%和62.9%,中位无进展生存期分别为6.5个月和6.2个月,差异均无统计学意义(P>0.05)。在生活质量和免疫功能改善以及疾病进展后接受二线治疗的患者比例方面,治疗组均优于观察组(P<0.05)。整个维持治疗过程中无治疗相关性死亡。结论对于晚期NSCLC,一线化疗后继续参一胶囊维持治疗可改善生活质量,提高免疫功能,有利于更多患者接受二线治疗,且安全性良好,值得进一步研究。Objective To investigate the clinical efficacy and safety of ginsenoside Rg3 maintenance therapy after the first-line chemotherapy for patients with advanced non-small cell lung cancer （NSCLC）. Method A total of 69 pa- tients who responded to the first-line chemotherapy were assigned to single-agent ginsenoside Rg3 maintenance therapy or clinical observation. The maintenance therapy continued until disease progresses or intolerable toxicity occurs. Result 2 patients in treatment group withdrew or lost follow-up, the ratio of progression in maintenance therapy group and obser- vation group were 53.1% vs 62.9% and the median progression-free survival time were, 6. 5 months vs 6.2 months, re- spectively, both of the two indexes were not significantly different （ P 〉 0. 05 ） , though there was significant difference in the elevation of T lymphocyte subset and life quality （ P 〈 0.05 ） , and there were also more patients in maintenance group received second-line therapy after tumor progressed （ P 〈 0.05 ）. Conclusion Maintenance therapy of ginsen- oside Rg3 is an effective treatment option for patients with advanced NSCLC who have not progressed after first-line thera- py, and is well tolerated.

关 键 词：非小细胞肺癌 参一胶囊 维持治疗 

分 类 号：R734.2[医药卫生—肿瘤]